Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age.
Madhi
Shabir A
SA
University of the Witwatersrand/Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, South Africa. madhis@hivas.com
Adrian
Peter
P
Kuwanda
Locadiah
L
Jassat
Wasilla
W
Jones
Stephanie
S
Little
Tessa
T
Soininen
Anu
A
Cutland
Clare
C
Klugman
Keith P
KP
D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006678:HIV / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007223:Infant; D008297:Male; D011008:Pneumococcal Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D022242:Pneumococcal Vaccines / Q000276:immunology* / Q000627:therapeutic use; D013296:Streptococcus pneumoniae / Q000276:immunology*; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000276:immunology / Q000627:therapeutic use
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate